



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>G01N 33/50</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/02045</b> (43) International Publication Date: 13 January 2000 (13.01.00)
<p>(21) International Application Number: PCT/BE99/00087</p> <p>(22) International Filing Date: 6 July 1999 (06.07.99)</p> <p>(30) Priority Data: 98870149.6 6 July 1998 (06.07.98) EP</p> <p>(71) Applicant (for all designated States except US): EURO-SCREEN S.A. [BE/BE]; Avenue des Becassines 7, B-1160 Brussels (BE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): DUPRIEZ, Vincent [BE/BE]; Avenue de Roodebeek 229, B-1030 Brussels (BE). DETHEUX, Michel [BE/BE]; Rue Charles de Loupoigne 13/102, B-1348 Louvain-La-Neuve (BE). PARMENTIER, Marc [BE/BE]; Chaussée d'Uccle 304, B-1630 Brussels (BE).</p> <p>(74) Agents: VAN MALDEREN, Eric et al.; Office Van Malderen, Place Reine Fabiola 6/1, B-1083 Brussels (BE).</p>		<p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: HIGH-THROUGHPUT SCREENING DIAGNOSTIC AND/OR DOSAGE METHOD OF AN AGONIST AND/OR AN ANTAGONIST FOR A CALCIUM-COUPLED RECEPTOR</p> <div data-bbox="357 1176 1266 1722"> </div> <p>(57) Abstract</p> <p>The present invention is related to a diagnostic and/or dosage method of an agonist and/or an antagonist and/or a modulator for a calcium-coupled receptor and/or channel and/or any other calcium-coupled protein, comprising the following successive steps: disposing the agonist and/or the antagonist and/or the modulator upon a solid support; incubating one or more cell(s) expressing apoaequorin and said calcium-coupled receptor with coelenterazine in order to reconstitute an active aequorin in said cell(s); adding to said solid support one or more of said cells; and obtaining the measurement of an emitted light by said cell(s). The present invention is also related to the diagnostic and/or dosage device intended for the method according to the invention.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

10 HIGH-THROUGHPUT SCREENING DIAGNOSTIC AND/OR DOSAGE METHOD  
OF AN AGONIST AND/OR AN ANTAGONIST FOR A CALCIUM-COUPLED  
RECEPTOR

Field of the invention

15 The present invention is related to a high-throughput screening diagnostic and/or dosage method and device of an agonist and/or an antagonist for a calcium-coupled receptor and the agonist and/or antagonist of said calcium-coupled receptor identified by said method and device.

20

Background of the invention and state of the art

A lot of G-protein-coupled receptors (GPCR) trigger, upon binding of an agonist, a transient increase in intracellular calcium concentration. This variation acts  
25 as an internal secondary messenger and is an important modulator of many physiological mechanisms (reviewed by Rink (1990), Tsunoda (1993) and by Santella & Carafoli (1997)). Measurement of intracellular calcium concentration in cells expressing a GPCR can thus be used to monitor the  
30 efficacy of activation of a GPCR by various compounds known - or suspected - to be a ligand for this GPCR.

The activation of other receptors such as ions channels may also induce an intracellular calcium concentration.

Changes in calcium concentration can be detected by several means and methods, like the use of fluorescent dyes (for example: fura-2, fluo-3, fluo-4 and indo-1).

5                   However,  $\text{Ca}^{++}$  sensitive dyes have limitations. Activation of the dyes with an excitation beam requires complicated and expensive instruments and limits the use of the plastic labware such as microtiter plates.

                  Another method for intracellular calcium  
10 concentration measurement is the use of cell lines overexpressing a GPCR and apoaequorin, such as described by Sheu et al. (1993). In this system, cells expressing apoaequorin are incubated with coelenterazine, which is the co-factor of aequorin. During this incubation,  
15 coelenterazine enters the cell and conjugates with apoaequorin to form aequorin, which is the active form of the enzyme. Upon incubation of the cells with an agonist of the GPCR, intracellular calcium concentration increases. This increase leads to the activation of the catalytic  
20 activity of aequorin, which oxidises coelenterazine and yields apoaequorin, coelenteramide,  $\text{CO}_2$  and light. Once the photon has been emitted, the complex must dissociate and apoaequorin must recombine with a new coelenterazine molecule to be able to emit light again. Thus, in this  
25 system, measurement of light emission following agonist addition reflects its ability to activate the GPCR and thus to increase intracellular calcium concentration. Because light is emitted only during 20 to 30 seconds after activation of the GPCR, recording of the emitted light must  
30 be performed during the few seconds following agonist addition to the cells. This flash-type signal is due to the fact that (1) intracellular calcium increase triggered by GPCR is only transient and (2) as mentioned earlier, after

oxidation of coelenterazine, apoaeguorin must recombine with coelenterazine to be able to emit light again.

The Patent Application EP-0341477 teaches the expression of jellyfish photoprotein aequorin in a mammalian cell system by cloning gene pAQ440 specifying the biosynthesis of the aequorin into an expression vector plasmid of a mammalian cell system, subjecting the resulting plasmid to transfection and producing the photoprotein aequorin in the mammalian cell.

10 The Patent US-5,422,266 describes a gene encoding apoaeguorin protein included in a vector capable of expressing the apoaeguorin in E. coli.

The Patent US-5,714,666 describes mammalian cell lines or transgenic animals expressing apoaeguorin and a receptor involved in the modulation of intracellular calcium. This document also describes a method of measuring intracellular calcium comprising adding coelenterazine cofactors to said mammalian cells expressing apoaeguorin and measuring photoemission where emission of photons is indicative of intracellular calcium concentration.

20 However, the methods of the state of the art require firstly the spreading of cells from a mammalian cell line expressing apoaeguorin on a solid support (for example a 96-well plate), secondly the addition of the coelenterazine cofactor upon the cells and incubation to reconstitute a functional aequorin, thirdly the preparation of the agent affecting a receptor involved in the modulation of intracellular calcium concentration, and its addition to the prepared cells, and finally the measurement of the photoemission.

30 Furthermore, as mentioned above, light is emitted only during 20 to 30 seconds after activation of the GPCR. Therefore, the recording of the emitted light

must be performed during the few seconds following agonist addition to the cells.

Therefore, the methods used in the state of the art are not adequate for a detection based upon high-throughput screening level, which usually need luminometer(s) and require the use of microtiter plates for the testing of thousands of compounds.

#### Aims of the invention

10 The present invention aims to provide a method and means, which do not present the drawbacks of the state of the art, for detecting biologically active substances, especially agonists and/or antagonists for calcium-coupled receptors.

15 A main aim of the present invention is to provide such method and means which allow the detection of biological active substances at a high-throughput scale, which could be adapted to specific recipients such as microtiter plates without requiring the modification of the  
20 high-throughput screening device.

Another aim of the present invention is to provide an easy and non-expensive method that could be easily automated.

#### 25 Summary of the invention

The present invention is related to a high-throughput screening diagnostic and/or dosage method of an agonist and/or an antagonist for a "calcium-coupled" receptor, comprising the following successive steps:

- 30 - disposing an agonist and/or an antagonist (preferably of a molecule) of said receptor upon a solid support,  
- incubating one or more cell(s) expressing apoaeguorin and said "calcium-coupled" receptor with coelenterazine

in order to reconstitute an active aequorin by said cell(s),

- adding to said solid support one or more of said cells, and
- 5 - obtaining the measurement of an emitted light by said cell(s).

The term "calcium-coupled" receptor means any receptor (such as a G-coupled receptor or an ion channel) whose activation (by an ion, a known or unknown agonist or  
10 antagonist molecule) may increase an intracellular calcium concentration in the cell comprising said receptor, preferably in its cytoplasmic membrane.

The terms "disposing... upon a solid support" means the step of putting said compound into a recipient  
15 such as a microtiter plate or any other solid support without requiring any (covalent or other) fixing of said compound to said solid support.

Advantageously, the solid support is a microtiter plate, preferably a 96-well microtiter plate.

20 Advantageously, the cell expressing apoaequorin and the calcium-coupled receptor is a cell expressing a G-coupled receptor and possibly one or more protein(s) intended to ensure a coupling of the receptor to the calcium pathway.

25 Preferably, said protein is selected from the group consisting of a natural Ga16 or Ga15 protein, a chimeric G-protein resulting from a fusion between two different G-proteins or a phospholipase C $\beta$ 2 protein.

The measurement of the emitted light is  
30 advantageously obtained with one or several luminometer(s), possibly equipped with several dispensers and measurement heads.

The present invention is also related to a high-throughput screening diagnostic and/or dosage device intended for the diagnostic and/or dosage method according to the invention, said device comprising the following elements:

- a recipient, preferably a microtiter plate, more preferably a 96-well microtiter plate,
- a medium containing cell(s) expressing apoaeguorin and a calcium-coupled receptor,
- 10 - a medium containing coelenterazine, and
- means (such as one or more luminometer(s) equipped with one or several dispensers and measurement heads) for detecting and possibly quantifying an emitted light by said cell(s).

15                   Advantageously, the device according to the invention comprises means for the automatic performance of the successive steps of the diagnostic and/or dosage method according to the invention.

A last aspect of the invention is related to  
20 the agonist and/or the antagonist of a calcium-coupled receptor identified by the method or the device according to the invention.

The present invention will be described in details in the following non-limiting examples, in  
25 reference to the enclosed figures.

#### Brief description of the drawings

Figure 1 shows a series curves representing the intensity of the emitted light by cells as a function of time for each well of a 96-well plate injected with cells expressing the CCR5 receptor, apoaeguorin and Gα16. The scaling is the same for all the graphs. Recording of  
30



the signal was performed for 30 seconds. Ligand concentrations are increasing from column 1 towards column 12. All measurements were performed in duplicate: lines A and B: ligand is RANTES; lines C and D: ligand is MIP-1 $\alpha$ ; lines E and F: ligand is MIP-1 $\beta$ ; lines G and H: ligand is derivative A of RANTES.

5

Figure 2 represents the dose-response curve for different agonists of the CCR5 receptor which represent RLU (integration of emitted light on 30 seconds) according to the logarithm of the final concentration of the ligand.

10

Figure 3 represents the dose-response curve for different agonists of the 5HT-2B receptor.

15

Figure 4 represents the dose-response curve of the light emitted from K562 cells expressing CCR3 and aequorin as a response to the activation of the receptor by eotaxin.

20 Figure 5 represents the dose-response curves for cells expressing aequorin and G $\alpha$ 16 and (panel A) the orexin 1 receptor or (panel B) the orexin 2 receptor.

Figure 6 represents the dose-response curve for different antagonists of the 5HT-2B receptor.

25

#### Description of a preferred embodiment of the present invention

Detection of agonistic activities by means of mammalian cell lines expressing apoaequorin and a GPCR requires the measurement of the emitted light to be performed just after placing the cells in contact with the potential agonist. This can easily be measured at low

30

throughput using a single-tube luminometer. However, up to now, this biological system could not be used at a high-throughput scale. Indeed:

- 5 (1) the necessity to measure light just after placing the cells in contact with the agonist to be tested compels to use a luminometer equipped with a build-in dispenser. For example, due to the short duration of light emission, it is impossible to inject the drugs to be tested on the cells placed in the 96 wells while  
10 the plate is outside the luminometer and to subsequently record emitted light with the plate into the luminometer. Even if the plate could rapidly (i.e. in less than 15 seconds) be placed into the luminometer after injection of the drugs to be tested,  
15 current apparatus do not allow the measurement of light from the 96 wells before the extinction of the flash signal of aequorin, as these luminometers are not equipped with 96 detectors.
- 20 (2) luminometers equipped with a build-in dispenser only allow to inject a single solution into the 96 wells, making it impossible to inject a different drug in each well. Moreover, the washing of the dispenser before each measurement, for the injection of another drug in the next well, is time-consuming and thus is  
25 not suitable for the high-throughput scale. The same problem occurs with devices equipped with 6 dispensers (e.g. the "Microbeta Jet" from EG&G Wallac) as the 6 dispensers only deliver a single solution.

The present invention provides a method for  
30 performing high-throughput screening of drugs binding to GPCR by the use of mammalian cell lines expressing apoaequorin and a GPCR and by the use of a conventional luminometer. Following this method, the solutions to be tested for (ant)agonistic activities are placed in the

wells of a 96-well plate. Cells expressing apoaequorin and a GPCR are detached from the culture plate (or collected from suspension cultures) and are incubated with coelenterazine to reconstitute active aequorin. These are  
5 then maintained in suspension with a magnetic stirrer and the cell suspension is injected, well by well, on the solutions of potential agonist to be tested. Light emission is then recorded for 1 (alternatively up to 30 or more) seconds. This method, by injecting the same cell suspension  
10 in each of the 96 wells, avoids the need of washing the dispenser between each measurement and allows to perform 96 measurements of agonist-induced aequorin light emission in 15 minutes or less with a single dispenser luminometer. Alternatively, it allows to perform 96 measurements of  
15 agonist-induced aequorin light emission in 2 minutes or less with a luminometer equipped with 6 dispensers and measurement heads (e.g. with the "Microbeta Jet" from EG&G Wallac).

This method thus allows to perform high-  
20 throughput screening (10 000 samples/day) with mammalian cell lines expressing apoaequorin and a GPCR and by the use of a conventional luminometer. This reduces the screening time and the amount of drugs needed for each measurement.

This system also allows to perform a  
25 functional screening with very few (down to 5000 or less) cells per measurement.

The injection of the cells into the wells containing the agonists did not increase the background of the measurement (that could for example have originated  
30 from cell breakage, releasing aequorin molecules from the cells into the culture medium, where the calcium concentration would have triggered the emission of light from aequorin). A signal-to-noise ratio above 50 was commonly obtained with this system of cell injection.

The method according to the invention is suitable for performing high-throughput analysis of GPCR or other calcium-coupled-receptor stimulation by known or potential agonists by means of cells expressing the receptor and apoaeguorin. These cells may express apoaeguorin in the cytoplasm, as described by Sheu et al. (1993) or Button and Brownstein (1993) or may express apoaeguorin in the mitochondria, by means of the addition of a mitochondrial targeting sequence to the aeguorin, as used by Stables et al. (1997) or in any other part of the cell. These cells may also express proteins intended to ensure coupling of the over-expressed receptor to the calcium pathway. These may be the natural G $\alpha$ 16 or G $\alpha$ 15 proteins (Milligan et al., 1996), chimeric G proteins resulting from a fusion between two different G proteins (Komatsuzaki et al., 1997), phospholipase C- $\beta$ 2 (Park et al., 1992), or any other "universal coupling" protein. Once the cells have been prepared and loaded with coelenterazine, they can be used for several hours (at least 9 hours). The load in coelenterazine and the intensity of the light emitted by the cells upon agonist stimulation lasts is stable for this period of time.

### Examples

#### 25 Example 1

A CHO cell line expressing the chemokine CCR-5 receptor, the G $\alpha$ 16 coupling protein and apoaeguorin was established. Cells were cultivated as a monolayer in HAM'sF12 medium containing 10% Foetal bovine serum (FBS). On the day of the experiment, the culture medium was removed and cells were incubated for 5 min at room temperature in PBS-EDTA (phosphate buffered saline solution without calcium, supplemented with 5 mM EDTA). Cells were

detached from the culture vessel by shaking the culture plate by hand and by pipetting up and down. Cells were centrifuged and the supernatant was removed to eliminate the EDTA; the pellet was resuspended in HAM's F12 culture medium without FBS and with 0.1% Bovine Serum Albumin. Cells were counted by means of a Thomas cell, were centrifuged again and were resuspended in HAM's F12 culture medium without FBS and with 0.1% Bovine Serum Albumin at a concentration of  $5 \cdot 10^6$  cells/ml. Coelenterazine (or a derivative of it, e.g. Coelenterazines f, h, n, cp or hcp, from Molecular Probes Inc.) at 500  $\mu$ M in methanol was added to the cell suspension at a final concentration of 5  $\mu$ M. The cell suspension was then stored in the dark at room temperature for 3 to 5 h, with shaking every 15 to 30 min to maintain the cells in suspension.

Series of dilutions of known ligands were prepared in HAM's F12 culture medium without FBS and with 0.1% Bovine Serum Albumin and 50  $\mu$ l of each of these solutions were placed in the wells of a 96-well plate. The cell suspension was diluted 5 times with medium HAM's F12 without FBS and with 0.1% Bovine Serum Albumin and was placed in a glass or plastic container protected from light by wrapping it with aluminium foil. A magnetic stirring bar was added to the suspension and a magnetic stirrer was used at low speed (1 to 5 rounds per second) to maintain the cells in an homogenous suspension. The magnetic stirring bar was equipped with a ring to avoid crushing the cells, and the subsequent release of aequorin in the culture medium. Alternatively, a culture vessel equipped for culture of cells in suspension may be used.

One uses the EG&G Wallac's MicroLumat-Plus microplate luminometer, which allows injection and direct subsequent recording of the emitted light from each well of

a 96-well plate. The end of the entrance tube of the dispenser was placed at the bottom of the cell suspension and the dispenser was washed with 3 times the dead volume of the apparatus so that all the volume of the tube and pumps was filled with the cell suspension. The 96-well plate containing the solutions of agonists was then inserted into the luminometer. Then, for each well, 50  $\mu$ l of the cell suspension (i.e. 100 000 cells) was dispensed into the well (at the lowest injection speed (0.4 s) to prevent cell breakage that would release aequorin into the culture medium) and the emitted light was immediately recorded during 30 seconds. After reading the first well, cells were injected into the next well and emitted light was recorded, etc. For each plate, a series of curves representing the intensity of the emitted light as a function of time for each well was displayed (figure 1). The intensity of the emitted light was integrated over 30 s using the Winglow software provided with the luminometer, yielding for each well one value representative of the emitted light and hence of the stimulation of the CCR-5 receptor by the agonist present in the well. These values can be plotted against the logarithm of the ligand concentration to generate dose-response curve as shown in figure 2. These allow the determination of half-maximal response doses ( $EC_{50}$ ) for each ligand. For the generation of these data, 288 measurements were performed in less than 3 hours.

### Example 2

30 A CHO cell line expressing the serotonin 5HT-2B receptor, the  $G\alpha_{16}$  coupling protein and apoaequorin was established. Cells were treated as described in Example 1 and were dispensed after dilution (100  $\mu$ l/well,

corresponding to 50 000 cells) on 100  $\mu$ l of solutions of known agonists for this receptor. The emitted light was recorded during 20 s for each well. Dose-response curves obtained for different agonists are shown in figure 3. For 5 the generation of these data, 144 measurements were performed in less than 1 hour.

#### Example 3

K562 cells expressing the chemokine CCR3 10 receptor were transfected by a plasmid for the expression of aequorin and the G $\alpha$ 16 coupling protein. Cells stably transfected were selected for 2 weeks with the antibiotic Zeocin. These cells were cultured in suspension in DMEM culture medium containing 10% FBS. They were centrifuged 15 and the pellet was used as described in example 1 to perform aequorin measurements. A dose-response curve with eotaxin and MCP-4 generated by this method is described in figure 4.

#### 20 Example 4

A CHO cell line expressing the orexin 1 or orexin 2 receptor, the G $\alpha$ 16 coupling protein and apoaequorin was established. Cells were treated as described in Example 1 and were dispensed after dilution 25 (100  $\mu$ l/well, corresponding to 25 000 cells) on 50  $\mu$ l of solutions of known agonists for these receptor. The emitted light was recorded during 20 s for each well. A dose-response curve obtained with this method is showed in figure 5 A.

30

#### Example 5

A CHO cell line expressing the cannabinoid CB1 receptor, the G $\alpha$ 16 coupling protein and apoaequorin was

established. Cells were treated as described in Example 1 and were dispensed after dilution (100  $\mu$ l/well, corresponding to 50 000 cells) on 100  $\mu$ l of solutions of a known agonist for this receptor. The emitted light was recorded during 20 s for each well. A dose-response curve obtained with this method is showed in figure 5 B.

For the measure of antagonistic activities, cells were injected on series of dilutions of antagonists. At this stage, the emitted light was recorded to check that the potential antagonists had no agonistic activity. The cells were incubated with the antagonists for 30 min. A solution of agonist (alpha-methyl-5HT) of the 5HT-2B receptor was then injected on the cells and the emitted light was immediately recorded for each well. The emitted light was plotted as a function of the logarithm of the antagonist concentration to yield the graph shown. Increasing antagonist concentrations result in a decreasing light emission upon agonist addition. An agonist of another receptor expressed by the cells (usually ATP, acting at P2 receptors) can then be injected on the mixture of antagonist, cells and agonists as a control to check that the cells still have active aequorin up to that moment of the experiment. For example, cytotoxic compounds that increase the intracellular calcium concentration can make the aequorin consume all the coelenterazine present in the cell. Such a cytotoxic compound will be detected by the absence of signal upon ATP injection (Fig. 6).



REFERENCES

- Button, D. & Brownstein, M., *Cell Calcium* 14, pp. 663-671 (1993)
- Komatsuzaki, K. et al., *FEBS Lett.* 406, pp. 165-170  
5 (1997)
- Milligan, G. et al., *TIPS* 17, pp. 235-237 (1996)
- Park, D. et al, *J. Biol. Chem.* 267, pp. 16048-16055 (1992).
- Rink, T.J., *FEBS Lett.* 268, pp. 381-385 (1990)
- 10 - Santella, L. & Carafoli, *FASEB J.* 11, pp. 1091-1109 (1997)
- Sheu, Y.-A. et al, *Analytical Biochemistry* 209, pp. 343-347 (1993)
- Stables, J. et al., *Analytical Biochemistry* 252, pp.  
15 115-126 (1997).
- Tsunoda, Y., *Biochim. Biophys. Acta* 1154, pp. 105-156 (1993)

CLAIMS

1. Diagnostic and/or dosage method of an agonist and/or an antagonist or any modulator for a calcium-coupled receptor or a calcium-coupled channel or  
5 any other calcium-coupled protein, comprising the following successive steps:

- disposing the agonist and/or the antagonist upon a solid support,
- incubating one or more cell(s) expressing apoaeguorin or  
10 any other related protein and said calcium-coupled receptor with coelenterazine or any other cofactor of a calcium-sensitive protein in order to reconstitute an active aequorin by said cell(s),
- adding to said solid support one or more of said cells,  
15 and
- obtaining the measurement of an emitted light by said cell(s).

2. Method according to claim 1, wherein the solid support is a microtiter plate.

20 3. Method according to claim 2, characterised in that the microtiter plate is a 96-well microtiter plate, or a 384-well plate, or a 1536-well-plate or any other format.

25 4. Method according to any one of the preceding claims, characterised in that the cell expresses apoaeguorin in the cytoplasm or in the mitochondria or in any other part of the cell.

30 5. Method according to any one of the preceding claims, wherein the cell expressing a calcium-coupled receptor is a cell expressing an endogenous or recombinant G-protein-coupled receptor and/or a cell which expresses proteins intended to ensure a coupling of the

analysed receptor (endogenous or overexpressed) to the calcium pathway.

6. Method according to claim 5, wherein said protein is selected from the group consisting of natural  
5 Gal6 or Gal5 protein, chimeric G-protein resulting from a fusion between two different G-proteins or phospholipase C $\beta$ 2 protein or any other coupling protein or chemical.


7. Method according to any one of the preceding claims, characterised in that the measurement of  
10 the emitted light is obtained with one or more luminometer(s), advantageously equipped with several dispensers and measurement heads.

8. High-throughput screening diagnostic and/or dosage device intended for the high-throughput  
15 screening diagnostic and/or dosage method according to any one of the preceding claims, comprising the following elements:

- a microtiter plate, preferably a 96-well microtiter plate,
- 20 - a medium containing cell(s) expressing apoaeguorin and a calcium-coupled receptor,
- a medium containing coelenterazine, and
- means for detecting an emitted light by said cell(s).

9. Device according to claim 8, comprising  
25 means for the automatic performance of the successive steps of the diagnostic and/or dosage method according to any one of the claims 1 to 7.

10. Agonist or antagonist of a receptor identified by the method according to any one of the claims  
30 1 to 8.

FIG.1




FIG. 2








FIG. 3

FIG. 4

**A.****FIG. 5A****B.****FIG. 5B**



FIG. 6

(19) World Intellectual Property Organization  
International Bureau



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

(43) International Publication Date  
13 January 2000 (13.01.2000)

PCT

(10) International Publication Number  
**WO 00/02045 A3**

(51) International Patent Classification<sup>4</sup>: G01N 33/50,  
33/566, 33/543

Loupoigne 13/102, B-1348 Louvain-La-Neuve (BE).  
PARMENTIER, Marc [BE/BE]; Chaussée d'Uccle 304,  
B-1630 Brussels (BE).

(21) International Application Number: PCT/BE99/00087

(74) Agents: VAN MALDEREN, Eric et al.; Office Van  
Malderen, Place Reine Fabiola 6/1, B-1083 Brussels (BE).

(22) International Filing Date: 6 July 1999 (06.07.1999)

(25) Filing Language:

English

(81) Designated States (national): CA, JP, US.

(26) Publication Language:

English

(84) Designated States (regional): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(30) Priority Data:  
98870149.6

6 July 1998 (06.07.1998) EP

Published:

— with international search report

(71) Applicant (for all designated States except US): EURO-  
SCREEN S.A. [BE/BE]; Route de Lemik 802, B-1160  
Brussels (BE).


(88) Date of publication of the international search report:  
8 November 2001

(72) Inventors; and

(75) Inventors/Applicants (for US only): DUPRIEZ, Vincent  
[BE/BE]; Avenue de Roodebeek 229, B-1030 Brussels  
(BE). DETHEUX, Michel [BE/BE]; Rue Charles de

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: BIOLUMINESCENT ASSAY FOR AGONISTS OR ANTAGONISTS OF A CALCIUM-COUPLED RECEPTOR



(57) Abstract: The present invention is related to a diagnostic and/or dosage method of an agonist and/or an antagonist and/or a modulator for a calcium-coupled receptor and/or channel and/or any other calcium-coupled protein, comprising the following successive steps: disposing the agonist and/or the antagonist and/or the modulator upon a solid support; incubating one or more cell(s) expressing apoaequorin and said calcium-coupled receptor with coelenterazine in order to reconstitute an active aequorin in said cell(s); adding to said solid support one or more of said cells; and obtaining the measurement of an emitted light by said cell(s). The present invention is also related to the diagnostic and/or dosage device intended for the method according to the invention.

WO 00/02045 A3

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/BE 99/00087

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/50 G01N33/566 G01N33/543

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 127, no. 23, 8 December 1997 (1997-12-08) Columbus, Ohio, US; abstract no. 314897, XP002121177 abstract & E. KNIGHT ET AL: "A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor" ANALYTICAL BIOCHEMISTRY, vol. 252, no. 1, 1997, pages 115-126, New York NY USA	1-10

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 November 1999

Date of mailing of the international search report

11/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Bohemen, C

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**